Gujarat Terce Laboratories (BSE: GUJTERC) had a P/E of 17.5× on 6 Nov 2026, below the industry P/E of 28.7×. Its ROCE of 23% is the highest among the 7 largest Drug Manufacturers (Specialty & Generic) peers, and sales grew 0.5% a year over 3 years. Debt is 0.13× equity. It is a small-cap company with a market cap of ₹36 Cr, ranked 136th of 154 Drug Manufacturers (Specialty & Generic) companies by market cap; the shares rose 1.8% over the past year.
- ₹47.95
- ₹50.00
- ₹46.01
- ₹46.67
- 17K
Health check
- ReturnsBehind
+1.8% over a year, better than 1 of 7 peers.
- Price tagCheaper
P/E 17.5 vs industry 28.7.
- GrowthSlow
Sales +0.5% a year over 3 years.
- ProfitabilityStrong
ROCE 23.4% vs peer median 17.9%.
- Balance sheetSolid
Debt 0.13× equity, interest covered 20.4×, Piotroski 6 of 9.
- Red flags1 to check
Quarterly sales down 17.1% on a year ago.
Small cap
Moves with the market
Key metrics
- Market cap
- ₹36 Cr
- Small cap
- P/E
- 17.5
- Industry 28.7
- Price to book
- 3.71
- Peers 4.99
- Dividend yield
- 0.00%
- ROE
- 27.2%
- Peers 14.7%
- ROCE
- 23.4%
- Peers 17.9%
- Debt to equity
- 0.13
- Debt ₹1.30 Cr
- EPS (TTM)
- ₹2.65
- OPM (TTM)
- 6.4%
- Net margin 4.5%
- Sales growth
- −17.1%
- Latest quarter vs a year ago
- Profit growth
- n/a
- Year-ago quarter not reported
- Price to sales
- 0.79
- EV/EBITDA 10.1
Strengths and risks
Strengths
- Return on equity of 27.2%.
- Return on capital employed of 23.4%.
- P/E of 17.5 against an industry P/E of 28.7.
- Positive operating cash flow in each of the last 4 years.
Risks to check
- Quarterly sales down 17.1% on a year ago.
About Gujarat Terce Laboratories
Gujarat Terce Laboratories Limited develops, manufactures, markets, and distributes medicines and healthcare products in India and internationally. The company offers generic pharmaceutical for therapeutic areas, such as antibiotics, respiratory, nutraceuticals, gastrology, gynecology, pain therapy, and ayurvedic. It provides tablets, capsules, oral liquids, ointments, and injections under the Acolate, Tynol, Resplash, Ferlit, Z-Oxi, Vitfol, Thyter,…
- Headquarters
- Ahmedabad
- Employees
- 234
- Sector
- Healthcare
- ISIN
- INE499G01013
- Website
- gujaratterce.in
Price range
- Avg volume (3M)
- 4.8K
- 1-year return
- plus 1.8%
- From 52-week high
- minus 7.4%
Peers · Drug Manufacturers - Specialty & Generic
| Company | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| SUNPHARMASun Pharmaceutical Industries | 1,860.00 | plus 1.69% | 4,46,276 | 40.7 | 4.99 | 17.9% | 13.1% | 28.2% | 10.4% | 10.6% | 0.86% | plus 8.2% |
| DIVISLABDivi's Laboratories | 10,320.50 | plus 1.78% | 2,73,977 | 93.6 | 16.35 | 19.0% | 16.2% | 34.9% | 11.0% | 12.1% | 0.29% | plus 49.0% |
| TORNTPHARMTorrent Pharmaceuticals | 4,750.00 | plus 0.85% | 1,80,675 | 80.2 | 9.83 | 9.1% | 15.7% | 33.7% | 13.3% | 20.2% | 0.80% | plus 31.7% |
| LAURUSLABSLaurus Labs | 2,340.00 | minus 0.26% | 1,26,433 | 94.4 | 20.86 | 19.5% | 24.0% | 30.4% | 3.8% | 4.0% | 0.09% | plus 138.6% |
| ZYDUSLIFEZydus Lifesciences | 1,197.90 | plus 0.41% | 1,19,491 | 28.6 | 4.29 | 19.0% | 14.7% | 26.2% | 16.5% | 37.0% | 0.08% | plus 22.8% |
| DRREDDYDr. Reddy's Laboratories | 1,373.00 | plus 0.51% | 1,14,462 | 40.9 | 2.96 | 14.2% | 7.3% | 15.9% | 11.0% | −1.7% | 0.58% | plus 13.8% |
| CIPLACipla | 1,411.00 | plus 0.49% | 1,13,993 | 39.4 | 3.22 | 14.9% | 8.3% | 17.3% | 7.2% | 11.5% | 0.92% | minus 6.6% |
| GUJTERCGujarat Terce Laboratories | 46.30 | minus 0.79% | 36 | 17.5 | 3.71 | 23.4% | 27.2% | 7.2% | 0.5% | – | 0.00% | plus 1.8% |
| Median of 7 peers | – | 0.51% | 1,26,433 | 40.9 | 4.99 | 17.9% | 14.7% | 28.2% | 11.0% | 11.5% | 0.58% | 22.8% |
Quarterly results
| ₹ Cr | Jun 25 | Sep 25 | Dec 25 | Mar 26 | Jun 26 |
|---|---|---|---|---|---|
| 10.9 | 12.9 | 12.3 | 11.4 | 9 | |
| 10.9 | 11 | 11.2 | 11 | 9.5 | |
| −0 | 1.9 | 1.1 | 0.4 | −0.5 | |
| −0.2% | 14.6% | 9.3% | 3.2% | −5.5% | |
| 0.1 | 0.1 | 0.1 | 0.5 | 0.5 | |
| 0 | 0.1 | 0 | 0 | 0 | |
| 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | |
| – | – | – | −0.5 | – | |
| −0.1 | 1.8 | 1.1 | 0.2 | −0.1 | |
| 38.7% | 21.3% | 32.5% | 50.7% | −19.7% | |
| −0 | 1.4 | 0.8 | 0.1 | −0.2 | |
| -0.06 | 1.80 | 0.95 | 0.13 | -0.23 |
Profit & loss
- Sales CAGR 3Y
- +0.5%
- ROE
- 27.2%
| ₹ Cr | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|
| 46.8 | 48 | 50.2 | 47.5 | |
| – | +2.5% | +4.6% | minus 5.4% | |
| 48.9 | 46.7 | 46.3 | 43.7 | |
| −2.1 | 1.3 | 3.9 | 3.8 | |
| −4.5% | 2.7% | 7.8% | 8.0% | |
| 0.3 | 0.3 | 0.3 | 0.3 | |
| 0.7 | 0.6 | 0.4 | 0.2 | |
| 0.4 | 0.4 | 0.4 | 0.4 | |
| −0.1 | −0 | −0 | −0.5 | |
| −2.9 | 0.5 | 3.4 | 3 | |
| 42.2% | 55.2% | 128.9% | 27.4% | |
| −1.7 | 0.2 | −1 | 2.2 | |
| -2.25 | 0.33 | -1.32 | 2.92 |
Forecast
Balance sheet
| ₹ Cr | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|
| 7.4 | 7.4 | 7.4 | 7.8 | |
| −0.6 | −0.3 | −0.9 | 1.9 | |
| 7.3 | 3.9 | 0.9 | 1.3 | |
| 14.4 | 12.3 | 15.4 | 13.5 | |
| 28.5 | 23.3 | 22.8 | 24.6 | |
| 4 | 3.7 | 3.7 | 3.2 | |
| 0.3 | 0.3 | 0.1 | 0 | |
| 2 | 0.1 | 1.8 | 4.2 | |
| 22.2 | 19.2 | 17.3 | 17.1 | |
| 28.5 | 23.3 | 22.8 | 24.6 |
Cash flow
| ₹ Cr | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|
| 0 | 2.6 | 3.1 | 1.7 | |
| 0.6 | −0.5 | 0.5 | −0.1 | |
| −0.1 | −4.1 | −2.8 | 0.5 | |
| 0.5 | −1.9 | 0.7 | 2.1 | |
| −0.1 | −0.1 | – | −0 | |
| −0 | 2.5 | 3.1 | 1.7 |
Shareholding pattern
This company is listed only on BSE, so there’s no NSE category split. See Major shareholders below for the named holders.
Major shareholders
Filings & events
News
No recent news coverage found.